OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2016.5328 OL-0-0-5328 Articles Identification of potential therapeutic targets for colorectal cancer by bioinformatics analysis YanMing SongMaomin BaiRixing ChengShi YanWenmao Department of General Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China Correspondence to: Dr Maomin Song, Department of General Surgery, Beijing Tiantan Hospital, Capital Medical University, 6 Tiantan Xili, Dongcheng, Beijing 100050, P.R. China, E-mail: maominsss@163.com 12 2016 31 10 2016 12 6 5092 5098 27052015 04102016 Copyright: © Yan et al. 2016 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The aim of the present study was to identify potential therapeutic targets for colorectal cancer (CRC). The gene expression profile GSE32323, containing 34 samples, including 17 specimens of CRC tissues and 17 of paired normal tissues from CRC patients, was downloaded from the Gene Expression Omnibus database. Following data preprocessing using the Affy and preprocessCore packages, the differentially-expressed genes (DEGs) between the two types of samples were identified with the Linear Models for Microarray Analysis package. Next, functional and pathway enrichment analysis of the DEGs was performed using the Database for Annotation Visualization and Integrated Discovery. The protein-protein interaction (PPI) network was established using the Search Tool for the Retrieval of Interacting Genes database. Utilizing WebGestalt, the potential microRNAs (miRNAs/miRs) of the DEGs were screened and the integrated miRNA-target network was built. A cohort of 1,347 DEGs was identified, the majority of which were mainly enriched in cell cycle-related biological processes and pathways. Cyclin-dependent kinase 1 (CDK1), cyclin B1 (CCNB1), MAD2 mitotic arrest deficient-like 1 (MAD2L1) and BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B) were prominent in the PPI network, while the over-represented genes in the integrated miRNA-target network were SRY (sex determining region Y)-box 4 (SOX4; targeted by hsa-mir-129), v-myc avian myelocytomatosis viral oncogene homolog (MYC; targeted by hsa-let-7c and hsa-mir-145) and cyclin D1 (CCND1; targeted by hsa-let-7b). CDK1, CCNB1 and CCND1 were also associated with the p53 signaling pathway. Overall, several genes associated with the cell cycle and p53 pathway were identified as biomarkers for CRC. CDK1, CCNB1, MAD2L1, BUB1B, SOX4, collagen type I α2 chain and MYC may play significant roles in CRC progression by affecting the cell cycle-related pathways, while CDK1, CCNB1 and CCND1 may serve as crucial regulators in the p53 signaling pathway. Furthermore, SOX4, MYC and CCND1 may be targets of miR-129, hsa-mir-145 and hsa-let-7c, respectively. However, further validation of these data is required.

 colorectal cancer differentially-expressed gene protein-protein interaction network miRNA-target network cell cycle p53 pathway Introduction

Colorectal cancer (CRC) is the third most common cancer type worldwide, with high morbidity and mortality rates (1). Annually, the global incidence of CRC is estimated to be ~1 million, with ~500,000 mortalities (2). Obesity, smoking, diet and a lack of exercise are risk factors associated with CRC (3). Despite advanced detection approaches, including colonoscopy and fecal immunochemical testing in early stage and precancerous lesions (4), the incidence of CRC remains high. In a previous study, in the United States in 2014, a cohort of 136,830 individuals was estimated to be diagnosed with CRC and 50,310 patient (36.8%) succumbed (5). In China, rapidly increasing incidence and mortality rates of CRC have been detected in past decades (6). Therefore, extensive studies have been conducted to investigate more effective biological therapies for CRC management. The accumulation of mutations in a large number of oncogenes and tumor suppressor genes, which could active or inhibit the pathways critical for the initiation and progression of CRC, were detected (7). Several biomarkers have been established for the detection of metastatic CRC, including KRAS and RAS mutations (8,9). Additionally, the crucial pathways were also observed. Smith et al showed that tumor protein p53 promoted the progression of CRC through the alteration of genetic pathways (10). The nuclear factor-κB signaling pathway was reported to contribute to the carcinogenesis of CRC (11). MicroRNAs (miRNAs/miRs) are small RNAs that play central roles in cancer development via the regulation of its target genes. The altered expression of miR-21, miR-31, miR-143 and miR-145 was implicated in CRC progression (12). A recent study recruiting a genome-wide screening method identified 16 vital genes in CRC, such as SCARA5, which was affected by methylation (13). However, the comprehensive regulatory mechanisms of CRC, particularly the interplayed associations between miRNAs and genes, remain obscure. The present study utilized the expression profile data in the study by Khamas et al (13) to identify the differentially-expressed genes (DEGs) between CRC tissues and paired normal control tissues. In addition, the interactions amongst the DEGs were further investigated through protein-protein interaction (PPI) network analysis. Furthermore, the miRNAs that targeted the DEGs were also predicted. As a whole, all these bioinformatical analyses were aimed to identify potential biomarkers for the prognosis and prevention of CRC, and to uncover the underlying regulatory mechanism of CRC progression.

 Materials and methods <sec> <title>Gene expression profile data

The gene expression profile data GSE32323, which was deposited by Khamas et al (13), was used. The public Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/), was utilized in the study. The platform used was GPL570 (Affymetrix Human Genome U133 Plus 2.0 Array; Agilent Technologies, Palo Alto, CA, USA). In the expression profile, there were 34 samples derived from the CRC patients, consisting of 17 from cancerous tissues (CRC samples) and 17 from paired normal tissues (control samples).

 Identification of DEGs

Following the data preprocessing, including background correction and the transformation from probe level to gene symbol using the Affy package (14) in R language (http://www.bioconductor.org/packages/release/bioc/html/affy.html), the data was subjected to normalization with the preprocessCore package (version 1.28.0; http://www.bioconductor.org/packages/3.0/bioc/html/preprocessCore.html) (15). Subsequently, the DEGs between CRC and normal samples were selected basing on a t-test of Linear Models for Microarray Analysis package in R (version 3.22.7; http://www.bioconductor.org/packages/release/bioc/html/limma.html) (16). The fold-change (FC) of the gene expression was also calculated. The threshold criteria for the DEG selection were P<0.05 and |log2FC| ≥1.

 Functional enrichment analysis of the DEGs

To investigate the functions and processes that may be altered by the identified DEGs, the Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed, using the online tool of the Database for Annotation Visualization and Integrated Discovery (version 6.7; http://david.abcc.Ncifcrf.gov/) (17), a potent program integrating the gene or protein functional annotations with graphical summary. The cut-off value for the screening of significant functions and pathways was P<0.05.

 Establishment of the PPI network

The Search Tool for the Retrieval of Interacting Genes (STRING) database (version 9.1; http://string-db.org/) (18) was recruited to predict the potential interactions amongst the identified DEGs from the protein level. Only the interactions containing at least one DEG were filtered out to build the PPI network, with the criterion of a combined score of >0.4, as visualized by Cytoscape (version 3.2.1; http://cytoscape.org/) software (19).

 Prediction of targets of microRNAs

Using the web-based gene set analysis toolkit (WebGestalt; Vanderbilt University, TN, USA; http://bioinfo.vanderbilt.edu/webgestalt/) (20), the regulatory miRNAs of the DEGs were selected.

 Results <sec> <title>DEGs between CRC and normal samples

According to the aforementioned selection criteria, a set of 1,347 DEGs, including 659 upregulated genes and 688 downregulated genes, were identified.

 Altered functions and pathways by the DEGs

As indicated in the results of the enrichment analysis (Table I), the upregulated DEGs were significantly enriched in biological processes (BPs) that included the mitotic cell cycle (GO:0000278), nuclear division (GO:0000280) and the cell cycle (GO:0007049), and pathways such as the cell cycle (Hsa04110) and DNA replication (Hsa03030). For the downregulated DEGs, the over-represented functional GO terms were cellular response to zinc ion (GO:0071294), cellular response to chemical stimulus (GO:0070887) and cellular response to chemical stimulus (GO:0070887), while the prominent pathways were metabolic pathways (Hsa01100) and pancreatic secretion (Hsa04972) (Table II).

 PPI network of the DEGs

By mapping the DEGs into the STRING database, the potential interactions of the DEGs from the protein level were predicted. As a result, a PPI network comprising 1,478 edges and 462 nodes were established. A protein in the network serves as a ‘node’, and the ‘degree’ of a node represents the number of the interactions between two nodes. Based on this definition, the top ten nodes with high degrees in the PPI network were cyclin-dependent kinase 1 (CDK1; degree=59), cyclin B1 (CCNB1; degree=48), NDC80 kinetochore complex component (degree=45), non-SMC condensin I complex, subunit G (degree=45), MAD2 mitotic arrest deficient-like 1 (MAD2L1; degree=44), centromere protein F (degree=41), BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B; degree=39), centromere protein A (degree=37), PDZ-binding kinase (degree=36) and TPX2, microtubule nucleation factor (degree=36) (Fig. 1).

 Integrated miRNA-target regulatory network

Using the WebGestalt software, the integrated miRNA-target network was built, consisting of 459 nodes (305 miRNAs and 154 DEGs) and 646 edges (Fig. 2). In this network, the notable genes that were targeted by multiple miRNAs included SRY (sex determining region Y)-box 4 (SOX4; targeted by 27 miRs, including hsa-mir-129, hsa-mir-133a/b and hsa-mir-204), CCND1 (cyclin D1; targeted by 21 miRs, including hsa-let-7b, hsa-mir-155, hsa-mir-16 and hsa-mir-195) and v-myc avian myelocytomatosis viral oncogene homolog (MYC; targeted by 10 miRs, including hsa-mir-34a, hsa-let-7c, hsa-mir-145 and hsa-mir-24.

 Discussion

CRC is one of the most lethal cancers in the world (3). Biomarker therapeutic methods may be the most effective approaches for the management of CRC. In the present study, a total of 1,347 DEGs (659 upregulated and 688 downregulated) were identified between CRC and normal tissues. Among them, CDK1, CCNB1, MAD2L1 and BUB1B, which are mainly enriched in cell cycle-related BPs and pathways, were also the predominant nodes in the PPI network. The integrated miRNA-target network identified crucial genes, including SOX4 (targeted by hsa-mir-129, hsa-mir-133a/b and hsa-mir-204), MYC (targeted by hsa-mir-34a, hsa-let-7c, hsa-mir-145 and hsa-mir-24) and CCND1 (targeted by hsa-let-7b, hsa-mir-155, hsa-mir-16 and hsa-mir-195), which were all enriched in cell cycle-related pathways. CDK1, CCNB1 and CCND1 were also associated with the p53 signaling pathways.

Cell cycle-related genes that promote the proliferation of endothelial cells contribute to the progression of tumor growth and metastasis of CRC (21). CDK1 encodes for a serine/threonine kinase that controls the eukaryotic cell cycle by regulating mitotic onset, as well as the centrosome cycle (22). CDK1 promotes cell proliferation via phosphorylation and inhibition of forkhead box O1 transcription factor (23). The alteration of CDK1 has been found in numerous cancer types, including breast cancer (24), esophageal adenocarcinoma (25) and oral squamous cell carcinoma (26). Deregulated CDK1 has been found in CRC (27), and it has been demonstrated that cantharidin, the traditional Chinese medicine that could induce cell cycle arrest and apoptosis in various cancers, exerted the anticancer function via the inhibition of CDK1 activity (28).

CCNB1 is a regulatory protein involved in mitosis (29). The increased expression of CCNB1 has also been observed in multiple cancer types, including non-small cell lung cancer (29) and gastrointestinal stromal tumors (30). Moreover, CCNB1 serves as a biomarker for the prognosis of estrogen receptor-positive breast cancer (31). CCNB1 plays important roles in the cell proliferation at the G2 phase. It was previously verified that the suppression of CCNB1 by miR-93 resulted in the inhibition of tumor growth in CRC (32).

MAD2L1 and BUB1B are two major mitotic spindle checkpoints. Previous studies considered that the mutation or deficiency in checkpoint proteins may contribute to enhancing the tumor development in breast cancer (33), and the mutation of BUB1, the paralog of BUB1B, was first reported in CRC (34). However, in contrast with these findings, Yuan et al validated the overexpression of MAD2L1 and BUB1B by reverse transcription-quantitative polymerase chain reaction in breast cancer and proposed that it may alternatively be the overexpression of checkpoint genes that account for genomic instability (35).

The high expression level of SOX4, the transcription factor responsible for the regulation of embryonic development and cell control, was significantly associated with the recurrence of CRC (36). Notably, it was reported that the oncogene SOX4 was regulated by miR-129-2 in endometrial cancer, and that the overexpression of SOX4 was partly caused by the suppression of miR-129-2 (37).

MYC is a central gene that plays important regulatory roles in cell cycle progression. The deficiency of c-MYC inhibited the proliferation of tumor cells in numerous cancer types during the cell cycle through G1 into S phase (38), while the upregulation of MYC transcription by the SNP rs6983267 was demonstrated to promote the development of CRC (39). Moreover, a spectrum of studies has reported the suppression of MYC by miRNAs, including let-7a (40), miR-23a/b (41) and miR-145 (42), in various cancer types. Furthermore, the overexpression of stromal genes, such as collagen type I α2 chain (COL1A2), was also detected in CRC (43).

In the present study, the aforementioned 7 genes were upregulated in CRC samples, and the genes were all enriched in cell cycle-related BP terms and pathways, implying that these genes mediated cell cycle pathways that may play a crucial role in the tumorigenesis and progression of CRC. Combining the previous confirmations with the present predicted miRNA-target interactions, it can be speculated that SOX4 may be the target of miR-129, while MYC may be targeted by hsa-mir-145 and hsa-let-7c.

The p53 protein acts as a tumor suppressor, as it could prevent DNA damage by promoting cell cycle arrest in the G1 phase or by apoptosis. The alteration of genes in the p53 signaling pathway is tightly correlated with cancer development (44) CCND1 is a cyclin protein that functions as a regulator of CDKs, such as CDK4 or CDK6, during the cell cycle G1/S transition. Amplification of CCND1 has been observed in CRC (45) and the association between increased CCND1 and the activation of the p53 pathway has been established (46). Besides, the involvement of CDK1 and CCNB1 in the p53 signaling pathway have also been implied (47,48). The present findings indicated that CDK1, CCNB1 and CCND1 were all enriched in the p53 signaling pathway, providing a hint that the three genes may have vital roles in the progression of CRC by the regulation of the p53 signaling pathway. An extensive number of miRNAs downregulated the expression of CCND1, including miR-193b (49), miR-200b (50), miR-138b (51) and let-7b (52). Based on the correlations in the integrated miRNA-target network, CCND1 was regulated by 21 miRNAs, including hsa-let-7c, suggesting that CCND1 may be the target of hsa-let-7c.

In conclusion, the cell cycle-related pathways mediated by the CDK1, CCNB1, MAD2L1, BUB1B, SOX4, COL1A2 and MYC genes, and the p53 signaling pathway regulated by the CDK1, CCNB1 and CCND1 genes may play important roles in the progression of CRC. All these genes may be used as biomarkers for the prognosis of CRC. Furthermore, SOX4 may be targeted by miR-129 and MYC by hsa-mir-145 and hsa-let-7c, while CCND1 may be the target of hsa-let-7c. However, further experimental validation is warranted to confirm these putative regulatory correlations.

 References QiuYPatwaTHXuLSheddenKMisekDETuckMJinGRuffinMTTurgeonDKSynalSPlasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blotJ Proteome Res716931703200810.1021/pr700706s18311904 CajusoTHänninenUAKondelinJGylfeAETanskanenTKatainenRPitkänenERistolainenHKaasinenETaipaleMExome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancerInt J Cancer135611623201410.1002/ijc.2870524382590 MendenhallWMAmosEHRoutWRZloteckiRAHochwaldSNCanceWGAdjuvant postoperative radiotherapy for colon carcinomaCancer10113381344200410.1002/cncr.2052615316945 QuinteroECastellsABujandaLCubiellaJSalasDLanasÁAndreuMCarballoFMorillasJDHernándezCColonoscopy versus fecal immunochemical testing in colorectal-cancer screeningN Engl J Med366697706201210.1056/NEJMoa110889522356323 SiegelRDesantisCJemalAColorectal cancer statistics, 2014CA Cancer J Clin64104117201410.3322/caac.2122024639052 HuangZHuangDNiSPengZShengWDuXPlasma microRNAs are promising novel biomarkers for early detection of colorectal cancerInt J Cancer127118126201010.1002/ijc.2500719876917 PinoMSChungDCThe chromosomal instability pathway in colon cancerGastroenterology13820592072201010.1053/j.gastro.2009.12.06520420946 PeetersMDouillardJYVan CutsemESienaSZhangKWilliamsRWiezorekJMutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: Assessment as prognostic and predictive biomarkers of response to panitumumabJ Clin Oncol31759765201310.1200/JCO.2012.45.149223182985 DouillardJYOlinerKSSienaSTaberneroJBurkesRBarugelMHumbletYBodokyGCunninghamDJassemJPanitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancerN Engl J Med36910231034201310.1056/NEJMoa130527524024839 SmithGCareyFABeattieJWilkieMJLightfootTJCoxheadJGarnerRCSteeleRJWolfCRMutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancerProc Natl Acad Sci USA9994339438200210.1073/pnas.12261289912093899 WangSLiuZWangLZhangXNF-kappaB signaling pathway, inflammation and colorectal cancerCell Mol Immunol6327334200910.1038/cmi.2009.4319887045 SlabyOSvobodaMFabianPSmerdovaTKnoflickovaDBednarikovaMNenutilRVyzulaRAltered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancerOncology72397402200710.1159/00011348918196926 KhamasAIshikawaTShimokawaKMogushiKIidaSIshiguroMMizushimaHTanakaHUetakeHSugiharaKScreening for epigenetically masked genes in colorectal cancer Using 5-Aza-2′-deoxycytidine, microarray and gene expression profileCancer Genomics Proteomics96775201222399497 GautierLCopeLBolstadBMIrizarryRAaffy-analysis of Affymetrix GeneChip data at the probe levelBioinformatics20307315200410.1093/bioinformatics/btg40514960456 BolstadBMPackage ‘preprocessCore’: A collection of pre-processing functionsR Package version 1.28.0http://www.bioconductor.org/packages/3.0/bioc/html/preprocessCore.html2013Accessed May 7, 2015 SmythGKLimma: Linear models for microarray dataBioinformatics and Computational Biology Solutions Using {R} and BioconductorGentlemanRCareyVDudoitSIrizarryRHuberWSpringerNew York397420200510.1007/0-387-29362-0_23 DennisGJrShermanBTHosackDAYangJGaoWLaneHCLempickiRADAVID: Database for annotation, visualization, and integrated discoveryGenome Biol4P3200310.1186/gb-2003-4-9-r6012734009 FranceschiniASzklarczykDFrankildSKuhnMSimonovicMRothALinJMinguezPBorkPvon MeringCJensenLJSTRING v9.1: Protein-protein interaction networks, with increased coverage and integrationNucleic Acids Res41(Database Issue)D808D815201310.1093/nar/gks109423203871 ShannonPMarkielAOzierOBaligaNSWangJTRamageDAminNSchwikowskiBIdekerTCytoscape: A software environment for integrated models of biomolecular interaction networksGenome Res1324982504200310.1101/gr.123930314597658 WangJDuncanDShiZZhangBWEB-based GEne SeT AnaLysis Toolkit (WebGestalt): Update 2013Nucleic Acids Res41W77W83201310.1093/nar/gkt43923703215 HongBSChoJHKimHChoiEJRhoSKimJKimJHChoiDSKimYKHwangDColorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cellsBMC Genomics10556200910.1186/1471-2164-10-55619930720 SantamaríaDBarrièreCCerqueiraAHuntSTardyCNewtonKCáceresJFDubusPMalumbresMBarbacidMCdk1 is sufficient to drive the mammalian cell cycleNature448811815200710.1038/nature0604617700700 LiuPKaoTPHuangHCDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factorOncogene2747334744200810.1038/onc.2008.10418408765 KimSJNakayamaSMiyoshiYTaguchiTTamakiYMatsushimaTTorikoshiYTanakaSYoshidaTIshiharaHNoguchiSDetermination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancerAnn Oncol196872200810.1093/annonc/mdm35817956886 HanselDEDharaSHuangRCAshfaqRDeaselMShimadaYBernsteinHSHarmonJBrockMForastiereACDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug targetAm J Surg Pathol29390399200510.1097/00000478-200503000-0001415725809 ChangJTWangHMChangKWChenWHWenMCHsuYMYungBYChenIHLiaoCTHsiehLLChengAJIdentification of differentially expressed genes in oral squamous cell carcinoma (OSCC): Overexpression of NPM, CDK1 and NDRG1 and underexpression of CHES1Int J Cancer114942949200510.1002/ijc.2066315645429 ThomsHCDunlopMGStarkLAp38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates nucleolar translocation of RelA and apoptosis in colorectal cancer cellsCancer Res6716601669200710.1158/0008-5472.CAN-06-103817308107 HuangWWKoSWTsaiHYChungJGChiangJHChenKTChenYCChenHYChenYFYangJSCantharidin induces G2/M phase arrest and apoptosis in human colorectal cancer colo 205 cells through inhibition of CDK1 activity and caspase-dependent signaling pathwaysInt J Oncol3810671073201121271215 SoriaJCJangSJKhuriFRHassanKLiuDHongWKMaoLOverexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implicationCancer Res6040004004200010945597 KoonNSchneider-StockRSarlomo-RikalaMLasotaJSmolkinMPetroniGZaikaABoltzeCMeyerFAnderssonLMolecular targets for tumour progression in gastrointestinal stromal tumoursGut53235240200410.1136/gut.2003.02123814724156 DingKLiWZouZZouXWangCCCNB1 is a prognostic biomarker for ER+ breast cancerMed Hypotheses83359364201410.1016/j.mehy.2014.06.01325044212 YangIPTsaiHLHouMFChenKCTsaiPCHuangSWChouWWWangJYJuoSHMicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycleCarcinogenesis3315221530201210.1093/carcin/bgs16622581829 ScintuMVitaleRPrencipeMGalloAPBonghiLValoriVMMaielloERinaldiMSignoriERabittiCGenomic instability and increased expression of BUB1B and MAD2L1 genes in ductal breast carcinomaCancer Lett254298307200710.1016/j.canlet.2007.03.02117498870 ShichiriMYoshinagaKHisatomiHSugiharaKHirataYGenetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survivalCancer Res621317200211782350 YuanBXuYWooJHWangYBaeYKYoonDSWerstoRPTullyEWilsbachKGabrielsonEIncreased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instabilityClin Cancer Res12405410200610.1158/1078-0432.CCR-05-090316428479 AndersenCLChristensenLLThorsenKSchepelerTSørensenFBVerspagetHWSimonRKruhøfferMAaltonenLALaurbergSØrntoftTFDysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancerBr J Cancer100511523200910.1038/sj.bjc.660488419156145 HuangYWLiuJCDeatherageDELuoJMutchDGGoodfellowPJMillerDSHuangTHEpigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancerCancer Res6990389046200910.1158/0008-5472.CAN-09-149919887623 WangHMannavaSGrachtchoukVZhuangDSoengasMSGudkovAVProchownikEVNikiforovMAc-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycleOncogene2719051915200810.1038/sj.onc.121082317906696 TakatsunoYMimoriKYamamotoKSatoTNiidaAInoueHImotoSKawanoSYamaguchiRTohHThe rs6983267 SNP is associated with MYC transcription efficiency, which promotes progression and worsens prognosis of colorectal cancerAnn Surg Oncol2013951402201310.1245/s10434-012-2657-z22976378 SampsonVBRongNHHanJYangQArisVSoteropoulosPPetrelliNJDunnSPKruegerLJMicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cellsCancer Res6797629770200710.1158/0008-5472.CAN-07-246217942906 GaoPTchernyshyovIChangTCLeeYSKitaKOchiTZellerKIDe MarzoAMVan EykJEMendellJTDangCVc-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolismNature458762765200910.1038/nature0782319219026 ChenZZengHGuoYLiuPPanHDengAHuJmiRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-MycJ Exp Clin Cancer Res29151201010.1186/1756-9966-29-15121092188 SmithMJCulhaneACDonovanMCoffeyJCBarryBDKellyMAHigginsDGWangJHKirwanWOCotterTGRedmondHPAnalysis of differential gene expression in colorectal cancer and stroma using fluorescence-activated cell sorting purificationBr J Cancer10014521464200910.1038/sj.bjc.660493119401702 VazquezABondEELevineAJBondGLThe genetics of the p53 pathway, apoptosis and cancer therapyNat Rev Drug Discov7979987200810.1038/nrd265619043449 Al-KurayaKNovotnyHBaviPSirajAKUddinSEzzatASaneaNAAl-DayelFAl-ManaHSheikhSSHER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancerJ Clin Pathol60768772200710.1136/jcp.2006.03828116882699 HuangHYIlleiPBZhaoZMazumdarMHuvosAGHealeyJHWexlerLHGorlickRMeyersPLadanyiMEwing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: A highly lethal subset associated with poor chemoresponseJ Clin Oncol23548558200510.1200/JCO.2005.02.08115659501 ChoiEJKimGHApigenin causes G(2)/M arrest associated with the modulation of p21(Cip1) and Cdc2 and activates p53-dependent apoptosis pathway in human breast cancer SK-BR-3 cellsJ Nutr Biochem20285290200910.1016/j.jnutbio.2008.03.00518656338 LiCJLiRWWangYHElsasserTHPathway analysis identifies perturbation of genetic networks induced by butyrate in a bovine kidney epithelial cell lineFunct Integr Genomics7193205200710.1007/s10142-006-0043-217186197 ChenJFeilotterHEParéGCZhangXPembertonJGGaradyCLaiDYangXTronVAMicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanomaAm J Pathol17625202529201010.2353/ajpath.2010.09106120304954 XiaWLiJChenLHuangBLiSYangGDingHWangFLiuNZhaoQMicroRNA-200b regulates cyclin D1 expression and promotes S-phase entry by targeting RND3 in HeLa cellsMol Cell Biochem344261266201010.1007/s11010-010-0550-220683643 LiuXLvXBWangXPSangYXuSHuKWuMLiangYLiuPTangJMiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogeneCell Cycle1124952506201210.4161/cc.2089822739938 SchultzJLorenzPGrossGIbrahimSKunzMMicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growthCell Res18549557200810.1038/cr.2008.4518379589

Protein-protein interaction network of the DEGs. Red nodes represent protein products of upregulated DEGs, green nodes represent protein products of downregulated DEGs and the lines between two nodes denote the interactions between them. DEGs, differentially-expressed genes.

Integrated miRNA-target regulatory network. Red circle nodes represent protein products of upregulated DEGs, green circle nodes represent protein products of downregulated DEGs, pink triangular nodes represent miRNAs and the lines between two nodes denote the interactions between them. DEGs, differentially-expressed genes; miRNA/miR, microRNA.

GO and pathway enrichment analysis of the upregulated DEGs (top 5 in each category, as ranked by the P-value).

Category ID Term Count P-value
BP GO:0000278 Mitotic cell cycle 102 2.63×10−24
BP GO:0000280 Nuclear division 55 2.26×10−22
BP GO:0007049 Cell cycle 128 3.47×10−21
BP GO:0007067 Mitosis 55 1.25×10−18
BP GO:0022402 Cell cycle process 117 1.15×10−18
CC GO:0031981 Nuclear lumen 140 1.68×10−17
CC GO:0044428 Nuclear region 158 2.32×10−16
CC GO:0043233 Organelle lumen 164 1.44×10−15
CC GO:0031974 Membrane-enclosed lumen 166 1.55×10−15
CC GO:0070013 Intracellular organelle lumen 161 2.22×10−15
MF GO:0005515 Protein binding 319 2.45×10−8
MF GO:0005488 Binding 450 1.92×10−6
MF GO:0003678 DNA helicase activity 9 2.10×10−5
MF GO:0004386 Helicase activity 15 1.42×10−4
MF GO:0008009 Chemokine activity 8 1.70×10−4
KEGG pathway Hsa04110 Cell cycle 24 1.21×10−11
KEGG pathway Hsa03030 DNA replication 11 3.64×10−8
KEGG pathway Hsa03013 RNA transport 21 1.19×10−7
KEGG pathway Hsa03008 Ribosome biogenesis in eukaryotes 15 1.60×10−7
KEGG pathway Hsa04115 p53 signaling pathway 10 1.72×10−4

GO, gene ontology; DEGs, differentially-expressed genes; KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological process; CC, cell component; MF, molecular function; Count, numbers of DEGs enriched in each term.

GO and pathway enrichment analysis of the downregulated DEGs (top 5 in each category, as ranked by the P-value).

Category ID Term Count P-value
BP GO:0071294 Cellular response to zinc ion 7 2.45×10−8
BP GO:0070887 Cellular response to chemical stimulus 112 2.90×10−7
BP GO:0010035 Response to inorganic substance 32 3.18×10−7
BP GO:0006629 Lipid metabolic process 77 4.91×10−7
BP GO:0050896 Response to stimulus 303 1.34×10−6
CC GO:0005615 Extracellular space 69 6.65×10−11
CC GO:0005576 Extracellular region 131 3.24×10−10
CC GO:0044421 Extracellular region part 81 1.11×10−9
CC GO:0071944 Cell periphery 224 1.50×10−9
CC GO:0016020 Membrane 346 6.02×10−9
MF GO:0019955 Cytokine binding 12 1.47×10−6
MF GO:0097367 Carbohydrate derivative binding 20 9.75×10−6
MF GO:0008201 Heparin binding 16 1.03×10−5
MF GO:0005539 Glycosaminoglycan binding 18 2.74×10−5
MF GO:0016616 Oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor 14 3.79×10−5
KEGG pathway Hsa01100 Metabolic pathways 69 1.21×10−4
KEGG pathway Hsa04972 Pancreatic secretion 12 6.96×10−4
KEGG pathway Hsa04960 Aldosterone-regulated sodium reabsorption 7 1.29×10−3
KEGG pathway Hsa00910 Nitrogen metabolism 5 1.90×10−3
KEGG pathway Hsa00232 Caffeine metabolism 3 2.02×10−3

GO, gene ontology; DEGS, differentially-expressed genes; KEGG, kyoto encyclopedia of genes and genomes; BP, biological process; CC, cell component; MF, molecular function; Count, numbers of DEGs enriched in each term.